Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:1
članak: 4 od 31  
Back povratak na rezultate
Srpski arhiv za celokupno lekarstvo
2017, vol. 145, br. 11-12, str. 646-651
jezik rada: engleski
vrsta rada: pregledni članak
objavljeno: 09/03/2018
doi: 10.2298/SARH170321147T
Uticaj savremenih oralnih antihiperglikemijskih lekova na disfunkcionalno masno tkivo
aKlinički centar Vojvodine, Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
bKlinički centar Vojvodine, Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Novi Sad
cUniverzitet u Novom Sadu, Medicinski fakultet

e-adresa: dragana.tomic-naglic@mf.uns.ac.rs

Sažetak

Gojaznost je bolest sa pandemijskom učestalošću, koju prate hronične metaboličke i organske komplikacije. Među najčešće metaboličke komplikacije gojaznosti spada tip 2 šećerne bolesti, a prvi korak u njenom lečenju je nutritivna terapija uz doziranu fizičku aktivnost i redukciju telesne mase. Medikamentno lečenje se započinje metforminom, a u slučaju neadekvatnog uspeha dodaju se i drugi antihiperglikemijski lekovi. Sa derivatima sulfonilureje postoji najveće kliničko iskustvo, ali je njihova upotreba ograničena jer izazivaju učestale hipoglikemije i porast telesne mase. U svetlu saznanja da je masno tkivo endokrini organ i da upravo disfunkcija ovog tkiva dovodi do hroničnih komplikacija, imperativ u savremenoj terapiji je upotreba lekova sa snažnim efektom na funkcionalnost ovog tkiva. Antihiperglikemijski lekovi izbora kog gojaznih osoba su oni koji dovode do maturacije adipocita, lučenja protektivnih adipocitokina i redistribucije masne mase iz visceralnih u subkutane depoe. Oralni hipoglikemijski agensi koji utiču na funkcionalnost masnog tkiva su metformin, SGLT-2 inhibitori, DPP-4 inhibitori i tiazolidindioni.

Ključne reči

Reference

Aronoff, S.L. (2017) Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. Postgraduate Medicine, 129(2): 231-241
Brunetti, L., Desantis, E.H. (2015) Patient tolerance and acceptance of colesevelam hydrochloride: focus on type 2 diabetes mellitus. Pharmacy and Therapeutics, 40(1): 62-7
Cadegiani, F.A., Silva, O.S. (2016) Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 9: 443-446
Chae, Y., Kim, T., Kim, M., Shin, C., Jung, I., Sohn, Y.S., Son, M. (2015) Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice. PLoS One, 10(12): e0144064
Chen, J., Sang, Z., Li, L., He, L., Ma, L. (2017) Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity. Molecular Diversity, 21(3): 637-654
Fujita, K., Iwama, H., Oura, K., Tadokoro, T., Hirose, K., Watanabe, M., Sakamoto, T., Katsura, A., Mimura, S., Nomura, T., Tani, J., Miyoshi, H., Morishita, A., Yoneyama, H., Okano, K., Suzuki, Y. (2016) Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. International Journal of Molecular Medicine, 38(4): 1135-1140
Hammarstedt, A., Rotter, S.V., Gogg, S., Jansson, P.-A., Smith, U. (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia, 48(1): 96-104
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., Whaley, J. M. (2008) Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats. Diabetes, 57(6): 1723-1729
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., i dr. (2017) Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol, 16(1): 8
Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R. (2015) Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1): 140-149
Koska, J., Lopez, L., d`Souza Karen,, Osredkar, T., Deer, J., Kurtz, J., Salbe, A.D., Harman, S.M., Reaven, P.D. (2017) Effect of liraglutide on dietary lipid-induced insulin resistance in humans. Diabetes, Obesity and Metabolism, 20(1): 69-76
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., Kim-Mitsuyama, S. (2016) Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovascular Diabetology, 15(1):
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J.G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Mannelin, M., Paturi, M., Sundvall, J. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet, 368(9548): 1673-1679
Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M.J., Johnsson, E., Eriksson, J.W. (2016) Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes, Obesity and Metabolism, 19(1): 49-60
Majdi, M.A., Mohammadzadeh, N.A., Lotfi, H., Mahmoudi, R., Alipour, F.G., Shool, F., Moghanloo, M.N., Porfaraj, S., Zarghami, N. (2017) Correlation of Resistin Serum Level with Fat Mass and Obesity-Associated Gene (FTO) rs9939609 Polymorphism in Obese Women with Type 2 Diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 11: S715-S720
Marathe, P.H., Gao, H.X., Close, K.L. (2017) American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of Diabetes, 9(4): 320-324
Pastel, E., Joshi, S., Knight, B., Liversedge, N., Ward, R., Kos, K. (2016) Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling. Nutrition & Diabetes, 6(12): e235-e235
Popovic, D.S., Stokic, E., Mitrovic, M., Tomic-Naglic, D., Pejin, R., Icin, T., Vukovic, B., Zivanovic, Z., Pejakovic, S., Kovacev-Zavisic, B. (2017) Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity. Current Vascular Pharmacology, 15(4):380-9
Popovic, D.S., Mitrovic, M., Tomic-Naglic, D., Icin, T., Bajkin, I., Vukovic, B., Benc, D., Zivanovic, Z., Kovacev-Zavisic, B., Stokic, E. (2017) The Wnt/Β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity. Current Neurovascular Research, 14(3):200-6
Popovic, D.S., Tomic-Naglic, D., Stokic, E. (2014) Relation of resistin, leptin and adiponectin - Trinity of adipose tissue dysfunction assessment. European Journal of Internal Medicine, 25(6): e80-e81
Ren, R., Chen, Z., Zhao, X., Sun, T., Zhang, Y., Chen, J., Lu, S., Ma, W. (2016) A possible regulatory link between Twist 1 and PPARγ gene regulation in 3T3-L1 adipocytes. Lipids in Health and Disease, 15(1): 189
Röhrborn, D., Brückner, J., Sell, H., Eckel, J. (2016) Reduced DPP4 activity improves insulin signaling in primary human adipocytes. Biochemical and Biophysical Research Communications, 471(3): 348-354
Sanlioglu, A.D., Altunbas, H.A., Balci, M.K., Griffith, T.S., Sanlioglu, S. (2013) Clinical utility of insulin and insulin analogs. Islets, 5(2): 67-78
Shivaprasad, C., Kalra, S. (2011) Bromocriptine in type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 15(5): 17
Srdić, B., Stokić, E.J., Korać, A.B., Ukropina, M., Vellčković, K., Breberina, M.B. (2010) Morphological characteristics of abdominal adipose tissue in normal-weight and obese women of different metabolic profiles. Exp Clin Endocrinol Diabetes, vol. 118, br. 10, str. 713-718
Stokić, E., Tomić-Naglić, D., Đerić, M., jorga J. (2009) Therapeutic options for treatment of cardiometabolic risk. Med Pregl, 62: 54-8
Stokić, E., Kupusinac, A., Tomic-Naglic, D., Smiljenic, D., Kovacev-Zavisic, B., Srdic-Galic, B., Soskic, S., Isenovic, E.R. (2015) Vitamin D and Dysfunctional Adipose Tissue in Obesity. Angiology, 66(7): 613-618
Stokić, E., Kupusinac, A., Tomić-Naglić, D., Zavišić, B.K., Mitrović, M., Smiljenić, D., Soskić, S., Isenović, E. (2015) Obesity and Vitamin D Deficiency. Angiology, 66(3): 237-243
Tan, B. K., Chen, J., Farhatullah, S., Adya, R., Kaur, J., Heutling, D., Lewandowski, K. C., o`Hare J. P., Lehnert, H., Randeva, H. S. (2009) Insulin and Metformin Regulate Circulating and Adipose Tissue Chemerin. Diabetes, 58(9): 1971-1977
Tomic-Naglic, D., Popovic, D.S., Mitrovic, M., Novakovic-Paro, J., Srdic-Galic, B., Ruzic, M., i dr. (2015) Ferritin and cardiovascular risk in obese persons. Int J Med Biomed Sci., 3: 12-7
Tomić-Naglić, D., Stokić, E., Srdić, B., Radovanov, T. (2008) Masno tkivo kao endokrina žlezda. Medicina danas, vol. 7, br. 4-6, str. 142-147
Virtanen, K. A., Hallsten, K., Parkkola, R., Janatuinen, T., Lonnqvist, F., Viljanen, T., Ronnemaa, T., Knuuti, J., Huupponen, R., Lonnroth, P., Nuutila, P. (2003) Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects. Diabetes, 52(2): 283-290
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22): 2117-2128